[go: up one dir, main page]

MX2018007440A - Forma de dosificacion por via oral de difenhidramina de disolucion rapida. - Google Patents

Forma de dosificacion por via oral de difenhidramina de disolucion rapida.

Info

Publication number
MX2018007440A
MX2018007440A MX2018007440A MX2018007440A MX2018007440A MX 2018007440 A MX2018007440 A MX 2018007440A MX 2018007440 A MX2018007440 A MX 2018007440A MX 2018007440 A MX2018007440 A MX 2018007440A MX 2018007440 A MX2018007440 A MX 2018007440A
Authority
MX
Mexico
Prior art keywords
dosage form
oral dosage
quick dissolving
diphenhydramine
diphenhydramine oral
Prior art date
Application number
MX2018007440A
Other languages
English (en)
Other versions
MX365216B (es
Inventor
Traboulsi Ashraf
John Dansereau Richard
LASTER Brian
Nicole Swigart Erin
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2018007440A publication Critical patent/MX2018007440A/es
Publication of MX365216B publication Critical patent/MX365216B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma de dosificación por vía oral para suministrar difenhidramina a través de la mucosa sublingual o bucal. La forma de dosificación por vía oral puede contener difenhidramina, o una sal farmacéuticamente aceptable de esta, un potenciador de la permeabilidad y un agente regulador. El agente regulador puede lograr un pH de aproximadamente 7.0 a aproximadamente 8.0. La difenhidramina puede disolverse totalmente en aproximadamente 2 minutos.
MX2018007440A 2015-12-18 2016-12-01 Forma de dosificacion por via oral de difenhidramina de disolucion rapida. MX365216B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/973,759 US9855227B2 (en) 2015-12-18 2015-12-18 Quick dissolving diphenhydramine oral dosage form
PCT/US2016/064367 WO2017105852A1 (en) 2015-12-18 2016-12-01 Quick dissolving diphenhydramine oral dosage form

Publications (2)

Publication Number Publication Date
MX2018007440A true MX2018007440A (es) 2018-11-09
MX365216B MX365216B (es) 2019-05-27

Family

ID=57570599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007440A MX365216B (es) 2015-12-18 2016-12-01 Forma de dosificacion por via oral de difenhidramina de disolucion rapida.

Country Status (5)

Country Link
US (3) US9855227B2 (es)
EP (1) EP3389625B1 (es)
CN (1) CN108366961B (es)
MX (1) MX365216B (es)
WO (1) WO2017105852A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855227B2 (en) 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form
EP3398590A1 (de) * 2017-05-02 2018-11-07 Stada Arzneimittel Ag Schmelztablette, enthaltend ein h1-antihistaminika
WO2020081761A1 (en) * 2018-10-19 2020-04-23 Shalon Ventures Research Llc Personalized drug dose dispenser and method
US20220249465A1 (en) * 2019-05-31 2022-08-11 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
CN114788817A (zh) * 2021-01-25 2022-07-26 南京宁丹新药技术有限公司 苯海拉明药物组合物
TR2022020579A2 (tr) * 2022-12-27 2024-06-21 Atatürk Üni̇versi̇tesi̇ Fi̇kri̇ Mülki̇yet Haklari Koordi̇natörlüğü Döner Sermaye İşletmesi̇ Alerji̇k hastaliklarin tedavi̇si̇ i̇çi̇n di̇fenhi̇drami̇n i̇le meti̇lpredni̇solonu kombi̇ne olarak i̇çeren di̇lalti tablet formülasyonlari

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
AU1323400A (en) 1998-10-27 2000-05-15 Fuisz Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2001089476A1 (en) 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2003092591A2 (en) 2002-04-30 2003-11-13 Npd Llc Multi-phasic delivery via transmucosal absorption of antiemetic medicaments
EP1444976A1 (en) 2003-02-10 2004-08-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US20060051413A1 (en) 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
RU2007127999A (ru) * 2004-12-23 2009-01-27 МакНЕЙЛ-ППС, ИНК. (US) Орально распадающееся фармацевтические композиции с сенсорными сигнальными агентами
US8097614B2 (en) 2005-02-17 2012-01-17 Velcera Pharmaceuticals, Inc. Transmucosal administration of meloxicam compositions for treating and preventing disorders in non-human domesticated animals
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
CN101754755A (zh) 2007-02-15 2010-06-23 德尔玛-杨有限公司 促进跨粘膜递送的组合物及方法
MX2010004265A (es) 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
MX2010006326A (es) * 2007-12-10 2010-10-04 Eurand Inc Comprimidos de desintegracion oral que comprenden difenhidramina.
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20090263476A1 (en) 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
WO2009153634A1 (en) 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A transmucosal delivery system
US9700548B2 (en) 2011-06-09 2017-07-11 Requis Pharmaceuticals Inc. Antihistamines combined with dietary supplements for improved health
CA2853117C (en) 2011-10-25 2018-08-07 Expermed S.A. Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
CN102488680B (zh) * 2011-12-21 2012-12-26 西南大学 布洛芬苯海拉明分散片及其制备方法
CN102440973B (zh) * 2011-12-21 2013-06-12 西南大学 枸橼酸苯海拉明口腔崩解片及其制备方法
CN102488681B (zh) 2011-12-21 2013-03-13 西南大学 布洛芬苯海拉明口腔崩解片及其制备方法
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
PL3003285T3 (pl) 2013-06-03 2022-06-20 Mcneil Ab Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
US9855227B2 (en) * 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form

Also Published As

Publication number Publication date
EP3389625B1 (en) 2021-11-17
CN108366961B (zh) 2022-02-18
EP3389625A1 (en) 2018-10-24
US20180078514A1 (en) 2018-03-22
US10085954B2 (en) 2018-10-02
US10624845B2 (en) 2020-04-21
US20170172948A1 (en) 2017-06-22
WO2017105852A1 (en) 2017-06-22
US9855227B2 (en) 2018-01-02
CN108366961A (zh) 2018-08-03
US20190015321A1 (en) 2019-01-17
MX365216B (es) 2019-05-27

Similar Documents

Publication Publication Date Title
MX2018007440A (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MY187047A (en) Selective pyy compounds and uses thereof
NZ762034A (en) Human plasma kallikrein inhibitors
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
IN2013MU03583A (es)
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
PH12016502246B1 (en) Carboxamide derivatives
MX2018011205A (es) Composiciones utiles en la prevencion y/o tratamiento de trastornos de la cavidad oral, vias aereas superiores y esofago.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
TR201717703A2 (tr) Api̇ksaban formülasyonlari
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
EP3659597A3 (en) Compositions and methods for drug sensitization of parasites
JO3435B1 (ar) تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان
MX2016003230A (es) Complejo lubricante para la boca.
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
IN2014MU00043A (es)
PH12016502059A1 (en) Fast dissolving granulate
IN2013MU03428A (es)
PH12016502527B1 (en) Stabilized desmopressin
TR201713325A2 (tr) Ri̇varoksaban i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇

Legal Events

Date Code Title Description
FG Grant or registration